Market: NASD |
Currency: USD
Address: 200 Arsenal Yards Boulevard
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Show more
📈 Kymera Therapeutics, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$60.37
-
Upside/Downside from Analyst Target:
37.61%
-
Broker Call:
40
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2025-11-06
-
EPS Estimate:
-0.82
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Kymera Therapeutics, Inc.
| Date | Reported EPS |
|---|
| 2025-11-06 (estimated upcoming) | - |
| 2025-08-11 | -0.95 |
| 2025-05-09 | -0.82 |
| 2025-02-27 | -0.89 |
| 2024-10-31 | -0.82 |
| 2024-08-07 | -0.58 |
| 2024-05-02 | -0.62 |
| 2024-02-22 | -0.25 |
| 2023-11-02 | -0.9 |
| 2023-08-03 | -0.67 |
| 2023-05-04 | -0.7 |
| 2023-02-23 | -0.59 |
| 2022-11-03 | -0.79 |
| 2022-08-09 | -0.78 |
| 2022-05-03 | -0.71 |
| 2022-02-24 | -0.67 |
| 2021-11-10 | -0.56 |
| 2021-08-06 | -0.55 |
| 2021-05-06 | -0.29 |
| 2021-03-11 | -0.29 |
| 2020-11-05 | -0.39 |
📰 Related News & Research
No related articles found for "kymera therapeutics".
